Trial results

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

NCT06131437 on ClinicalTrials.gov · last registry update 2026-02-06

Finished 8 December 2025, after enrolling 809 people. Primary outcome, as filed: To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

809

Started

2023-11-27

Primary completion

2025-12-08 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

To confirm non-inferiority of CagriSema versus tirzepatide: Relative change in body weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.